Given that the TI signature reflected poor clinical outcomes of metastatic melanoma patients (Figures 3, 6), we sought for potential drugs that could inhibit the function of the genes in the TI signature which was annotated as the MYC-related pathway (Figure 2). Here, MYC is linked to metastatic melanoma.